19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2523
HELPLINE: 1-877-530-0002



SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace





powered by centersite dot net
Women's Health
Basic InformationLatest News
What Works Best for Women Struggling With a Leaky Bladder?Even Housework, Gardening Can Help an Older Woman's HeartAHA News: Black Woman in Their 50s Face Especially High Stroke RiskEarly-Onset Menstruation Linked to Later High Blood Pressure RiskClaire's Recalls 3 Cosmetic Products Due to Possible Asbestos ContaminationScientists Spot Clues to Predicting Breast Cancer's ReturnAre Some Birth Control Methods Doomed to Fail?AHA News: Belly Fat Ups Older Women's Heart Risks, Even Without ObesityHormone Therapy Linked to Slight Rise in Alzheimer's RiskFDA Issues Asbestos Warning About Some Claire's Cosmetic ProductsHigh Deductibles May Threaten Breast Cancer Patients' SurvivalHow Soon Should You Conceive After a Stillbirth?Lifestyle Changes Can Lower Your Breast Cancer RiskPrenatal Vitamins Might Lower Risk of Second Child With AutismLong Work Weeks May Be Depressing, Especially for WomenSingle Moms Often Put Kids' Health Care First, Study FindsCervical 'Microbiome' Could Help Predict Cancer RiskDon't Be Fooled: Thermography No Substitute for Mammograms, FDA SaysWhat's the Right Age to Test for Osteoporosis?Most Nations May Be Rid of Cervical Cancer By 2100HPV Infections Most Tied to Cancer Are in Decline, and Vaccines May Be WhyExperimental Drug Helps Women With Deadly Type of Breast CancerAHA News: Why Are Black Women at Higher Risk of Dying From Pregnancy Complications?Acupuncture Could Help Ease Menopausal SymptomsAHA News: Could 'Cardio-Obstetrics' Curb Rise in Pregnancy-Related Deaths?Should You Get Tested for the 'Breast Cancer Genes'?Common Yeast Infection Treatment Tied to Miscarriage, Birth DefectsHeart Attacks Rising Among Younger WomenBreast Cancer and DDT: Timing of Exposure May MatterCould Diet Sodas Raise an Older Woman's Stroke Risk?Mammograms Helped Save Up to 600,000 U.S. Lives Since 1989: StudyAHA News: Pregnancy May Raise Risk of Deadliest Type of StrokeAHA News: Many Women Plagued by Anxiety After StrokeBenign Ovarian Cysts Should Be Left in Place, Study SuggestsToo Much TV Raises Women's Odds for Early-Onset Colon Cancer: StudyWomen's Brains May Be More 'Age-Resistant' Than Men'sHealth Screenings Every Woman NeedsAHA: Could a Heart Attack or Stroke Lead to Early Menopause?Breast Cancer May Bring Higher Odds for A-fib, TooHealth Tip: Help Prevent Cervical CancerUterus 'Scratching' Technique Won't Boost Fertility Treatment SuccessMoms, Are You Victims of 'Invisible Labor'?Mindfulness Might Ease Menopause SymptomsBody Size May Influence Longevity in Women, But Not MenHPV Vaccine Even Helps Women Who Didn't Get It: StudyAt Risk for Breast Cancer? Your Race MattersTwo-Thirds of Poor U.S. Women Can't Afford Menstrual Pads, Tampons: StudyVaccine, Screening Can Prevent Cervical Cancer DeathsAHA: Breastfeeding May Help a Mom's HeartAI Beats Humans at Detecting Cervical Precancers
Questions and AnswersVideosLinksBook ReviewsSelf-Help Groups
Related Topics

Wellness and Personal Development
Mental Disorders

Experimental Drug Helps Women With Deadly Type of Breast Cancer

HealthDay News
by By Steven ReinbergHealthDay Reporter
Updated: Feb 20th 2019

new article illustration

WEDNESDAY, Feb. 20, 2019 (HealthDay News) -- An experimental drug has shown promise in extending the lives of women suffering from a particularly aggressive and deadly type of breast cancer, according to the results of a phase 2 trial.

Right now, the standard treatment of chemotherapy for metastatic triple-negative breast cancer has not been very effective. That might change with the new drug, called sacituzumab govitecan, which combines an antibody with a chemotherapy drug to better target cancer cells.

In the trial, funded by the drug's maker, about a third of the patients responded to treatment and the effect lasted up to eight months, said study senior author Dr. Kevin Kalinsky.

"These patients had a significant reduction of their cancer," he added. "This is an exciting new therapeutic."

About 50 percent had some response and saw a slowing of cancer progression for about five months, he noted.

Kalinsky, an oncologist at the Irving Medical Center at New York-Presbyterian-Columbia University, also noted: "This is a patient population where we really need new therapeutics."

Triple-negative breast cancer represents about 15 percent of all breast cancer and is most often seen in young women and black women, although why it affects these women isn't known, according to Dr. J. Leonard Lichtenfeld, the interim chief medical officer at the American Cancer Society.

The cancer is different from other breast cancers because tumor cells don't have protein HER2 (human epidermal growth factor receptor 2), estrogen receptors or progesterone receptors, which means that hormonal treatment or drugs that target HER2 are ineffective. Chemotherapy shrinks or slows its progress in only about 10 percent to 15 percent of these patients, and the effect only lasts about two to three months, the researchers said.

Survival for women with metastatic triple-negative breast cancer is around a year, and that has not changed for 20 years, they noted.

In this phase 2 trial, 108 women who had failed treatment with other drugs were treated with sacituzumab govitecan. The drug combines an antibody to the Trop-2 antigen, which is found on most breast cancer cells, with the chemotherapy drug irinotecan.

When the antibody latches onto the Trop-2 molecules of the cancer cells, the drug is released within cells and into the areas of the tumor. This targeted delivery allows the chemotherapy drug to reach cancer cells and helps reduce the toxic effect of the drug to healthy cells, the researchers said.

The trial lasted from June 2013 to February 2017 and was funded by New Jersey-based Immunomedics.

Patients were given the drug for as long as they benefited from treatment, and eight women were still on the drug as of December 2017. The average time of treatment was more than five months, which was longer than the average 2.5 months with patients' other treatments, the researchers found.

Some of the drug's side effects included nausea, diarrhea and a drop in white blood cells. Researchers said these symptoms were manageable.

The drug is not yet available, Kalinsky said. A phase 3 trial comparing sacituzumab govitecan with other treatments for triple-negative breast cancer is now underway.

"This is a step forward for women where there were not any real treatment options," said Lichtenfeld, who was not involved with the study. "It was not a cure -- we still have a long way to go."

He added that the drug might be more effective if it were given earlier, when the cancer was still confined to the breast.

"Even with these results, however, it represents a better outcome than any of the treatments used in this form of breast cancer," Lichtenfeld said.

The report was published Feb. 20 in the New England Journal of Medicine.

More information

The American Cancer Society offers more information on breast cancer.